MAY 08, 2019 6:00 AM PDT

Novel DNA Methylation in Mammals

C.E. Credits: CEU
Speaker
  • Tao Wu, PhD

    Assistant Professor, CPRIT Scholar for Cancer Research, Department of Molecular and Human Genetics, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
    BIOGRAPHY

Abstract

Genetic drivers of cancer can be dysregulated through epigenetic modifications of DNA. Although the critical role of DNA 5-methylcytosine (5mC) in the regulation of transcription is recognized, the functions of other non-canonical DNA modifications remain obscure. We report the identification of novel DNA N6-methyladenine (N6-mA) modifications in human tissues and implicate this epigenetic mark in human disease, specifically the highly malignant brain cancer glioblastoma. Glioblastoma markedly upregulated N6-mA levels, which co-localized with heterochromatic histone modifications, predominantly H3K9me3. N6-mA levels were dynamically regulated by the DNA demethylase ALKBH1, depletion of which led to transcriptional silencing of oncogenic pathways through decreasing chromatin accessibility. Targeting the N6-mA regulator ALKBH1 in patient-derived human glioblastoma models inhibited tumor cell proliferation and extended the survival of tumor-bearing mice, supporting this novel DNA modification as a potential therapeutic target for glioblastoma. 

Furthermore, ALKBH1 controls the hypoxia responding genes in glioblastoma. Collectively, our results uncover a novel epigenetic node in cancer through the DNA modification N6-mA. The regulators of this new modification could serve as novel therapeutic targets in cancer therapy.

Learning Objectives: 

1. Get cutting-edge knowledge of epigenetics
2. Learning the application of 3rd generation SMRT sequencing in novel DNA methylation discovery
 


You May Also Like
MAY 08, 2019 6:00 AM PDT

Novel DNA Methylation in Mammals

C.E. Credits: CEU


Loading Comments...